 | • レポートコード：MRC2-11QY14438 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はプロテアソーム阻害剤のグローバル市場について調査・分析したレポートです。種類別（ボルテゾミブ、カルフィルゾミブ、イキサゾミブ）市場規模、用途別（病院、クリニック、腫瘍学センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別プロテアソーム阻害剤の競争状況、市場シェア ・世界のプロテアソーム阻害剤市場：種類別市場規模 2015年-2020年（ボルテゾミブ、カルフィルゾミブ、イキサゾミブ） ・世界のプロテアソーム阻害剤市場：種類別市場規模予測 2021年-2026年（ボルテゾミブ、カルフィルゾミブ、イキサゾミブ） ・世界のプロテアソーム阻害剤市場：用途別市場規模 2015年-2020年（病院、クリニック、腫瘍学センター） ・世界のプロテアソーム阻害剤市場：用途別市場規模予測 2021年-2026年（病院、クリニック、腫瘍学センター） ・北米のプロテアソーム阻害剤市場分析：米国、カナダ ・ヨーロッパのプロテアソーム阻害剤市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのプロテアソーム阻害剤市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のプロテアソーム阻害剤市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのプロテアソーム阻害剤市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Johnson & Johnson、Takeda Pharmaceutical、Millennium Pharmaceuticals、MimiVAx、TG Therapeutics ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Proteasome inhibitors are drugs that block the action of proteasomes, cellular complexes that break down proteins.
Proteasome inhibitors are being studied in the treatment of cancer and are used in treating multiple myeloma.
Market Analysis and Insights: Global Proteasome Inhibitors Market
The global Proteasome Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Proteasome Inhibitors Scope and Market Size
Proteasome Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Proteasome Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Proteasome Inhibitors market is segmented into
Bortezomib
Carfilzomib
Ixazomib
Segment by Application, the Proteasome Inhibitors market is segmented into
Hospital
Clinics
Oncology Centres
Regional and Country-level Analysis
The Proteasome Inhibitors market is analysed and market size information is provided by regions (countries).
The key regions covered in the Proteasome Inhibitors market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Proteasome Inhibitors Market Share Analysis
Proteasome Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Proteasome Inhibitors business, the date to enter into the Proteasome Inhibitors market, Proteasome Inhibitors product introduction, recent developments, etc.
The major vendors covered:
Johnson & Johnson
Takeda Pharmaceutical
Millennium Pharmaceuticals
MimiVAx
TG Therapeutics
…
1 Study Coverage
1.1 Proteasome Inhibitors Product Introduction
1.2 Market Segments
1.3 Key Proteasome Inhibitors Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Proteasome Inhibitors Market Size Growth Rate by Type
1.4.2 Bortezomib
1.4.3 Carfilzomib
1.4.4 Ixazomib
1.5 Market by Application
1.5.1 Global Proteasome Inhibitors Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Oncology Centres
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Proteasome Inhibitors Market Size, Estimates and Forecasts
2.1.1 Global Proteasome Inhibitors Revenue 2015-2026
2.1.2 Global Proteasome Inhibitors Sales 2015-2026
2.2 Global Proteasome Inhibitors, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Proteasome Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Proteasome Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Proteasome Inhibitors Competitor Landscape by Players
3.1 Proteasome Inhibitors Sales by Manufacturers
3.1.1 Proteasome Inhibitors Sales by Manufacturers (2015-2020)
3.1.2 Proteasome Inhibitors Sales Market Share by Manufacturers (2015-2020)
3.2 Proteasome Inhibitors Revenue by Manufacturers
3.2.1 Proteasome Inhibitors Revenue by Manufacturers (2015-2020)
3.2.2 Proteasome Inhibitors Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Proteasome Inhibitors Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Proteasome Inhibitors Revenue in 2019
3.2.5 Global Proteasome Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Proteasome Inhibitors Price by Manufacturers
3.4 Proteasome Inhibitors Manufacturing Base Distribution, Product Types
3.4.1 Proteasome Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Proteasome Inhibitors Product Type
3.4.3 Date of International Manufacturers Enter into Proteasome Inhibitors Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Proteasome Inhibitors Market Size by Type (2015-2020)
4.1.1 Global Proteasome Inhibitors Sales by Type (2015-2020)
4.1.2 Global Proteasome Inhibitors Revenue by Type (2015-2020)
4.1.3 Proteasome Inhibitors Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Proteasome Inhibitors Market Size Forecast by Type (2021-2026)
4.2.1 Global Proteasome Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global Proteasome Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 Proteasome Inhibitors Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Proteasome Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Proteasome Inhibitors Market Size by Application (2015-2020)
5.1.1 Global Proteasome Inhibitors Sales by Application (2015-2020)
5.1.2 Global Proteasome Inhibitors Revenue by Application (2015-2020)
5.1.3 Proteasome Inhibitors Price by Application (2015-2020)
5.2 Proteasome Inhibitors Market Size Forecast by Application (2021-2026)
5.2.1 Global Proteasome Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global Proteasome Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global Proteasome Inhibitors Price Forecast by Application (2021-2026)
6 North America
6.1 North America Proteasome Inhibitors by Country
6.1.1 North America Proteasome Inhibitors Sales by Country
6.1.2 North America Proteasome Inhibitors Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Proteasome Inhibitors Market Facts & Figures by Type
6.3 North America Proteasome Inhibitors Market Facts & Figures by Application
7 Europe
7.1 Europe Proteasome Inhibitors by Country
7.1.1 Europe Proteasome Inhibitors Sales by Country
7.1.2 Europe Proteasome Inhibitors Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Proteasome Inhibitors Market Facts & Figures by Type
7.3 Europe Proteasome Inhibitors Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Proteasome Inhibitors by Region
8.1.1 Asia Pacific Proteasome Inhibitors Sales by Region
8.1.2 Asia Pacific Proteasome Inhibitors Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Proteasome Inhibitors Market Facts & Figures by Type
8.3 Asia Pacific Proteasome Inhibitors Market Facts & Figures by Application
9 Latin America
9.1 Latin America Proteasome Inhibitors by Country
9.1.1 Latin America Proteasome Inhibitors Sales by Country
9.1.2 Latin America Proteasome Inhibitors Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Proteasome Inhibitors Market Facts & Figures by Type
9.3 Central & South America Proteasome Inhibitors Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Proteasome Inhibitors by Country
10.1.1 Middle East and Africa Proteasome Inhibitors Sales by Country
10.1.2 Middle East and Africa Proteasome Inhibitors Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Proteasome Inhibitors Market Facts & Figures by Type
10.3 Middle East and Africa Proteasome Inhibitors Market Facts & Figures by Application
11 Company Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Description and Business Overview
11.1.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Johnson & Johnson Proteasome Inhibitors Products Offered
11.1.5 Johnson & Johnson Related Developments
11.2 Takeda Pharmaceutical
11.2.1 Takeda Pharmaceutical Corporation Information
11.2.2 Takeda Pharmaceutical Description and Business Overview
11.2.3 Takeda Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Takeda Pharmaceutical Proteasome Inhibitors Products Offered
11.2.5 Takeda Pharmaceutical Related Developments
11.3 Millennium Pharmaceuticals
11.3.1 Millennium Pharmaceuticals Corporation Information
11.3.2 Millennium Pharmaceuticals Description and Business Overview
11.3.3 Millennium Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Millennium Pharmaceuticals Proteasome Inhibitors Products Offered
11.3.5 Millennium Pharmaceuticals Related Developments
11.4 MimiVAx
11.4.1 MimiVAx Corporation Information
11.4.2 MimiVAx Description and Business Overview
11.4.3 MimiVAx Sales, Revenue and Gross Margin (2015-2020)
11.4.4 MimiVAx Proteasome Inhibitors Products Offered
11.4.5 MimiVAx Related Developments
11.5 TG Therapeutics
11.5.1 TG Therapeutics Corporation Information
11.5.2 TG Therapeutics Description and Business Overview
11.5.3 TG Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.5.4 TG Therapeutics Proteasome Inhibitors Products Offered
11.5.5 TG Therapeutics Related Developments
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Description and Business Overview
11.1.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Johnson & Johnson Proteasome Inhibitors Products Offered
11.1.5 Johnson & Johnson Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Proteasome Inhibitors Market Estimates and Projections by Region
12.1.1 Global Proteasome Inhibitors Sales Forecast by Regions 2021-2026
12.1.2 Global Proteasome Inhibitors Revenue Forecast by Regions 2021-2026
12.2 North America Proteasome Inhibitors Market Size Forecast (2021-2026)
12.2.1 North America: Proteasome Inhibitors Sales Forecast (2021-2026)
12.2.2 North America: Proteasome Inhibitors Revenue Forecast (2021-2026)
12.2.3 North America: Proteasome Inhibitors Market Size Forecast by Country (2021-2026)
12.3 Europe Proteasome Inhibitors Market Size Forecast (2021-2026)
12.3.1 Europe: Proteasome Inhibitors Sales Forecast (2021-2026)
12.3.2 Europe: Proteasome Inhibitors Revenue Forecast (2021-2026)
12.3.3 Europe: Proteasome Inhibitors Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Proteasome Inhibitors Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Proteasome Inhibitors Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Proteasome Inhibitors Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Proteasome Inhibitors Market Size Forecast by Region (2021-2026)
12.5 Latin America Proteasome Inhibitors Market Size Forecast (2021-2026)
12.5.1 Latin America: Proteasome Inhibitors Sales Forecast (2021-2026)
12.5.2 Latin America: Proteasome Inhibitors Revenue Forecast (2021-2026)
12.5.3 Latin America: Proteasome Inhibitors Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Proteasome Inhibitors Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Proteasome Inhibitors Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Proteasome Inhibitors Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Proteasome Inhibitors Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Proteasome Inhibitors Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Proteasome Inhibitors Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Proteasome Inhibitors Market Segments
Table 2. Ranking of Global Top Proteasome Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Proteasome Inhibitors Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Bortezomib
Table 5. Major Manufacturers of Carfilzomib
Table 6. Major Manufacturers of Ixazomib
Table 7. Global Proteasome Inhibitors Market Size Growth Rate by Application 2020-2026 (K Units)
Table 8. Global Proteasome Inhibitors Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 9. Global Proteasome Inhibitors Sales by Regions 2015-2020 (K Units)
Table 10. Global Proteasome Inhibitors Sales Market Share by Regions (2015-2020)
Table 11. Global Proteasome Inhibitors Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Proteasome Inhibitors Sales by Manufacturers (2015-2020) (K Units)
Table 13. Global Proteasome Inhibitors Sales Share by Manufacturers (2015-2020)
Table 14. Global Proteasome Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Proteasome Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Proteasome Inhibitors as of 2019)
Table 16. Proteasome Inhibitors Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Proteasome Inhibitors Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Proteasome Inhibitors Price (2015-2020) (USD/Unit)
Table 19. Proteasome Inhibitors Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Proteasome Inhibitors Product Type
Table 21. Date of International Manufacturers Enter into Proteasome Inhibitors Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Proteasome Inhibitors Sales by Type (2015-2020) (K Units)
Table 24. Global Proteasome Inhibitors Sales Share by Type (2015-2020)
Table 25. Global Proteasome Inhibitors Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Proteasome Inhibitors Revenue Share by Type (2015-2020)
Table 27. Proteasome Inhibitors Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 28. Global Proteasome Inhibitors Sales by Application (2015-2020) (K Units)
Table 29. Global Proteasome Inhibitors Sales Share by Application (2015-2020)
Table 30. North America Proteasome Inhibitors Sales by Country (2015-2020) (K Units)
Table 31. North America Proteasome Inhibitors Sales Market Share by Country (2015-2020)
Table 32. North America Proteasome Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Proteasome Inhibitors Revenue Market Share by Country (2015-2020)
Table 34. North America Proteasome Inhibitors Sales by Type (2015-2020) (K Units)
Table 35. North America Proteasome Inhibitors Sales Market Share by Type (2015-2020)
Table 36. North America Proteasome Inhibitors Sales by Application (2015-2020) (K Units)
Table 37. North America Proteasome Inhibitors Sales Market Share by Application (2015-2020)
Table 38. Europe Proteasome Inhibitors Sales by Country (2015-2020) (K Units)
Table 39. Europe Proteasome Inhibitors Sales Market Share by Country (2015-2020)
Table 40. Europe Proteasome Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Proteasome Inhibitors Revenue Market Share by Country (2015-2020)
Table 42. Europe Proteasome Inhibitors Sales by Type (2015-2020) (K Units)
Table 43. Europe Proteasome Inhibitors Sales Market Share by Type (2015-2020)
Table 44. Europe Proteasome Inhibitors Sales by Application (2015-2020) (K Units)
Table 45. Europe Proteasome Inhibitors Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Proteasome Inhibitors Sales by Region (2015-2020) (K Units)
Table 47. Asia Pacific Proteasome Inhibitors Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Proteasome Inhibitors Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Proteasome Inhibitors Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Proteasome Inhibitors Sales by Type (2015-2020) (K Units)
Table 51. Asia Pacific Proteasome Inhibitors Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Proteasome Inhibitors Sales by Application (2015-2020) (K Units)
Table 53. Asia Pacific Proteasome Inhibitors Sales Market Share by Application (2015-2020)
Table 54. Latin America Proteasome Inhibitors Sales by Country (2015-2020) (K Units)
Table 55. Latin America Proteasome Inhibitors Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Proteasome Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Proteasome Inhibitors Revenue Market Share by Country (2015-2020)
Table 58. Latin America Proteasome Inhibitors Sales by Type (2015-2020) (K Units)
Table 59. Latin America Proteasome Inhibitors Sales Market Share by Type (2015-2020)
Table 60. Latin America Proteasome Inhibitors Sales by Application (2015-2020) (K Units)
Table 61. Latin America Proteasome Inhibitors Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Proteasome Inhibitors Sales by Country (2015-2020) (K Units)
Table 63. Middle East and Africa Proteasome Inhibitors Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Proteasome Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Proteasome Inhibitors Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Proteasome Inhibitors Sales by Type (2015-2020) (K Units)
Table 67. Middle East and Africa Proteasome Inhibitors Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Proteasome Inhibitors Sales by Application (2015-2020) (K Units)
Table 69. Middle East and Africa Proteasome Inhibitors Sales Market Share by Application (2015-2020)
Table 70. Johnson & Johnson Corporation Information
Table 71. Johnson & Johnson Description and Major Businesses
Table 72. Johnson & Johnson Proteasome Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 73. Johnson & Johnson Product
Table 74. Johnson & Johnson Recent Development
Table 75. Takeda Pharmaceutical Corporation Information
Table 76. Takeda Pharmaceutical Description and Major Businesses
Table 77. Takeda Pharmaceutical Proteasome Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Takeda Pharmaceutical Product
Table 79. Takeda Pharmaceutical Recent Development
Table 80. Millennium Pharmaceuticals Corporation Information
Table 81. Millennium Pharmaceuticals Description and Major Businesses
Table 82. Millennium Pharmaceuticals Proteasome Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Millennium Pharmaceuticals Product
Table 84. Millennium Pharmaceuticals Recent Development
Table 85. MimiVAx Corporation Information
Table 86. MimiVAx Description and Major Businesses
Table 87. MimiVAx Proteasome Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. MimiVAx Product
Table 89. MimiVAx Recent Development
Table 90. TG Therapeutics Corporation Information
Table 91. TG Therapeutics Description and Major Businesses
Table 92. TG Therapeutics Proteasome Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. TG Therapeutics Product
Table 94. TG Therapeutics Recent Development
Table 95. Global Proteasome Inhibitors Sales Forecast by Regions (2021-2026) (K Units)
Table 96. Global Proteasome Inhibitors Sales Market Share Forecast by Regions (2021-2026)
Table 97. Global Proteasome Inhibitors Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 98. Global Proteasome Inhibitors Revenue Market Share Forecast by Regions (2021-2026)
Table 99. North America: Proteasome Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 100. North America: Proteasome Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 101. Europe: Proteasome Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 102. Europe: Proteasome Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Asia Pacific: Proteasome Inhibitors Sales Forecast by Region (2021-2026) (K Units)
Table 104. Asia Pacific: Proteasome Inhibitors Revenue Forecast by Region (2021-2026) (US$ Million)
Table 105. Latin America: Proteasome Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 106. Latin America: Proteasome Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 107. Middle East and Africa: Proteasome Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 108. Middle East and Africa: Proteasome Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 110. Key Challenges
Table 111. Market Risks
Table 112. Main Points Interviewed from Key Proteasome Inhibitors Players
Table 113. Proteasome Inhibitors Customers List
Table 114. Proteasome Inhibitors Distributors List
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Proteasome Inhibitors Product Picture
Figure 2. Global Proteasome Inhibitors Sales Market Share by Type in 2020 & 2026
Figure 3. Bortezomib Product Picture
Figure 4. Carfilzomib Product Picture
Figure 5. Ixazomib Product Picture
Figure 6. Global Proteasome Inhibitors Sales Market Share by Application in 2020 & 2026
Figure 7. Hospital
Figure 8. Clinics
Figure 9. Oncology Centres
Figure 10. Proteasome Inhibitors Report Years Considered
Figure 11. Global Proteasome Inhibitors Market Size 2015-2026 (US$ Million)
Figure 12. Global Proteasome Inhibitors Sales 2015-2026 (K Units)
Figure 13. Global Proteasome Inhibitors Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Proteasome Inhibitors Sales Market Share by Region (2015-2020)
Figure 15. Global Proteasome Inhibitors Sales Market Share by Region in 2019
Figure 16. Global Proteasome Inhibitors Revenue Market Share by Region (2015-2020)
Figure 17. Global Proteasome Inhibitors Revenue Market Share by Region in 2019
Figure 18. Global Proteasome Inhibitors Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Proteasome Inhibitors Revenue in 2019
Figure 20. Proteasome Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Proteasome Inhibitors Sales Market Share by Type (2015-2020)
Figure 22. Global Proteasome Inhibitors Sales Market Share by Type in 2019
Figure 23. Global Proteasome Inhibitors Revenue Market Share by Type (2015-2020)
Figure 24. Global Proteasome Inhibitors Revenue Market Share by Type in 2019
Figure 25. Global Proteasome Inhibitors Market Share by Price Range (2015-2020)
Figure 26. Global Proteasome Inhibitors Sales Market Share by Application (2015-2020)
Figure 27. Global Proteasome Inhibitors Sales Market Share by Application in 2019
Figure 28. Global Proteasome Inhibitors Revenue Market Share by Application (2015-2020)
Figure 29. Global Proteasome Inhibitors Revenue Market Share by Application in 2019
Figure 30. North America Proteasome Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 31. North America Proteasome Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Proteasome Inhibitors Sales Market Share by Country in 2019
Figure 33. North America Proteasome Inhibitors Revenue Market Share by Country in 2019
Figure 34. U.S. Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 35. U.S. Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 37. Canada Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Proteasome Inhibitors Market Share by Type in 2019
Figure 39. North America Proteasome Inhibitors Market Share by Application in 2019
Figure 40. Europe Proteasome Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 41. Europe Proteasome Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Proteasome Inhibitors Sales Market Share by Country in 2019
Figure 43. Europe Proteasome Inhibitors Revenue Market Share by Country in 2019
Figure 44. Germany Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 45. Germany Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 47. France Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 49. U.K. Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 51. Italy Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 53. Russia Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Proteasome Inhibitors Market Share by Type in 2019
Figure 55. Europe Proteasome Inhibitors Market Share by Application in 2019
Figure 56. Asia Pacific Proteasome Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 57. Asia Pacific Proteasome Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Proteasome Inhibitors Sales Market Share by Region in 2019
Figure 59. Asia Pacific Proteasome Inhibitors Revenue Market Share by Region in 2019
Figure 60. China Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 61. China Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 63. Japan Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 65. South Korea Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 67. India Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 69. Australia Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 71. Taiwan Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 73. Indonesia Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 75. Thailand Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 77. Malaysia Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 79. Philippines Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 81. Vietnam Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Proteasome Inhibitors Market Share by Type in 2019
Figure 83. Asia Pacific Proteasome Inhibitors Market Share by Application in 2019
Figure 84. Latin America Proteasome Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 85. Latin America Proteasome Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Proteasome Inhibitors Sales Market Share by Country in 2019
Figure 87. Latin America Proteasome Inhibitors Revenue Market Share by Country in 2019
Figure 88. Mexico Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 89. Mexico Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 91. Brazil Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 93. Argentina Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Proteasome Inhibitors Market Share by Type in 2019
Figure 95. Latin America Proteasome Inhibitors Market Share by Application in 2019
Figure 96. Middle East and Africa Proteasome Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 97. Middle East and Africa Proteasome Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Proteasome Inhibitors Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Proteasome Inhibitors Revenue Market Share by Country in 2019
Figure 100. Turkey Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 101. Turkey Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 103. Saudi Arabia Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Proteasome Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 105. U.A.E Proteasome Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Proteasome Inhibitors Market Share by Type in 2019
Figure 107. Middle East and Africa Proteasome Inhibitors Market Share by Application in 2019
Figure 108. North America Proteasome Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 109. North America Proteasome Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Proteasome Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. Europe Proteasome Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Proteasome Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Asia Pacific Proteasome Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Proteasome Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Latin America Proteasome Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Proteasome Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Middle East and Africa Proteasome Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
ユビキチンプロテアソームの世界市場（～2026年） Market Analysis and Insights: Global Ubiquitin Proteasome Market The global Ubiquitin Proteasome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Ubiquitin Proteasome Scope and Market Size Ubiquitin Proteasome market is…- 20sプロテアソームの世界市場（～2026年） Market Analysis and Insights: Global 20s Proteasome Market The global 20s Proteasome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global 20s Proteasome Scope and Market Size 20s Proteasome market is segmented by Type, and …
- TNF阻害剤の世界市場（～2026年） TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…
- シグナル伝達阻害剤の世界市場（～2026年） Signal transduction inhibitors are drugs that may prevent the ability of cancer cells to multiply quickly and invade other tissues. Growing need for effective cancer diagnostics and innovative therapies for cancer treatment are expected to be the major factors driving the signal transduction inhibit…
- DPP IV阻害剤（DPP-4阻害剤）の世界市場（～2026年） DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of in…